Finoriq research workspace
Zenas BioPharma, Inc. (ZBIO) Historical Metrics
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development. Review ZBIO fundamentals, ratios, and historical filing metrics on Finoriq.
Company Snapshot
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
- Company
- Zenas BioPharma, Inc. (ZBIO)
- Ticker
- ZBIO
- Market Cap
- $1.9B
- Latest Price
- $30.76
- Industry
- Biotech & Pharma
Zenas BioPharma, Inc. (ZBIO) Current Valuation Metrics
Static valuation preview for Zenas BioPharma, Inc. (ZBIO). Market data retrieved 2026-07-08. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| P/SMarket cap divided by latest TTM revenue. | 178x | Revenue | TTM FY 2025 |
| Earnings YieldLatest TTM net income divided by market cap. | -21.2% | Net Income | TTM FY 2025 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -9.7% | Operating Cash Flow | TTM FY 2025 |
| Price / BookMarket cap divided by stockholders' equity. | 7.36x | Stockholders' Equity | FY 2025 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.